JP2022533578A5 - - Google Patents
Info
- Publication number
- JP2022533578A5 JP2022533578A5 JP2021566974A JP2021566974A JP2022533578A5 JP 2022533578 A5 JP2022533578 A5 JP 2022533578A5 JP 2021566974 A JP2021566974 A JP 2021566974A JP 2021566974 A JP2021566974 A JP 2021566974A JP 2022533578 A5 JP2022533578 A5 JP 2022533578A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- patient
- tumor
- treatment agent
- antibody molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1906807.1 | 2019-05-14 | ||
| GBGB1906807.1A GB201906807D0 (en) | 2019-05-14 | 2019-05-14 | Dosages regimes for the administration of lag-3/pd-l1 bispectic antibody |
| GB1914040.9 | 2019-09-30 | ||
| GB201914040A GB201914040D0 (en) | 2019-09-30 | 2019-09-30 | Dosage regimes for the administration of lag-3/pd-l1 bispecific antibody |
| GBGB2000318.2A GB202000318D0 (en) | 2020-01-09 | 2020-01-09 | Dosage regimes for the administration of LAG-3/PD-L1 bispecific antibody |
| GB2000318.2 | 2020-01-09 | ||
| PCT/EP2020/063529 WO2020229626A1 (en) | 2019-05-14 | 2020-05-14 | Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022533578A JP2022533578A (ja) | 2022-07-25 |
| JP2022533578A5 true JP2022533578A5 (https=) | 2023-05-17 |
Family
ID=70775359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566974A Pending JP2022533578A (ja) | 2019-05-14 | 2020-05-14 | Ｌａｇ－３／ｐｄ－ｌ１二重特異性抗体の投与のための投与計画 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220275092A1 (https=) |
| EP (1) | EP3969477A1 (https=) |
| JP (1) | JP2022533578A (https=) |
| KR (1) | KR20220008316A (https=) |
| CN (1) | CN114206939A (https=) |
| AU (1) | AU2020275209A1 (https=) |
| BR (1) | BR112021022831A2 (https=) |
| CA (1) | CA3139003A1 (https=) |
| IL (1) | IL287979A (https=) |
| MX (1) | MX2021013943A (https=) |
| SG (1) | SG11202112136RA (https=) |
| WO (1) | WO2020229626A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201811184UA (en) | 2016-06-20 | 2019-01-30 | F Star Beta Ltd | Lag -3 binding members |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| ES3044118T3 (en) | 2018-07-12 | 2025-11-26 | Invox Pharma Ltd | Antibody molecules that bind cd137 and ox40 |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| PT3820569T (pt) | 2018-07-12 | 2025-01-14 | Invox Pharma Ltd | Moléculas de anticorpo que se ligam a pd-l1 e cd137 |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| JP7850884B2 (ja) * | 2021-03-31 | 2026-04-24 | メルス・ベー・フェー | 新規多重特異性抗体 |
| US20240101718A1 (en) * | 2022-09-28 | 2024-03-28 | Incyte Corporation | Anti-pd-1/lag-3 bispecific antibodies and uses thereof |
| GB202304278D0 (en) | 2023-03-23 | 2023-05-10 | F Star Therapeutics Ltd | Dosage regimens for the administration of a bispecific antibody in combination with chemotherapy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20210602T1 (hr) * | 2016-06-20 | 2021-05-14 | F-Star Delta Limited | Vezujuće molekule koje vežu pd-l1 i lag-3 |
| ES2965352T3 (es) * | 2017-05-30 | 2024-04-12 | Bristol Myers Squibb Co | Tratamiento de tumores positivos a gen 3 de activación de linfocitos (LAG-3) |
| JP2020522495A (ja) * | 2017-05-30 | 2020-07-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物 |
-
2020
- 2020-05-14 AU AU2020275209A patent/AU2020275209A1/en not_active Abandoned
- 2020-05-14 MX MX2021013943A patent/MX2021013943A/es unknown
- 2020-05-14 CA CA3139003A patent/CA3139003A1/en active Pending
- 2020-05-14 US US17/610,873 patent/US20220275092A1/en not_active Abandoned
- 2020-05-14 WO PCT/EP2020/063529 patent/WO2020229626A1/en not_active Ceased
- 2020-05-14 EP EP20726768.3A patent/EP3969477A1/en not_active Withdrawn
- 2020-05-14 JP JP2021566974A patent/JP2022533578A/ja active Pending
- 2020-05-14 KR KR1020217040782A patent/KR20220008316A/ko not_active Ceased
- 2020-05-14 SG SG11202112136RA patent/SG11202112136RA/en unknown
- 2020-05-14 BR BR112021022831A patent/BR112021022831A2/pt unknown
- 2020-05-14 CN CN202080051441.8A patent/CN114206939A/zh active Pending
-
2021
- 2021-11-10 IL IL287979A patent/IL287979A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022533578A5 (https=) | ||
| Boku et al. | Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4) | |
| Cohen et al. | A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282 | |
| JP2019521087A5 (https=) | ||
| CN104114168A (zh) | 治疗增殖性疾病的联合疗法(威罗菲尼和mdm2抑制剂) | |
| TW201839399A (zh) | 癌症治療 | |
| JP2023542093A (ja) | 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用 | |
| JP7750884B2 (ja) | ＨＩＦ－２α阻害剤とレンバチニブの組み合わせを使用して、癌またはフォンヒッペル・リンダウ病を処置するための方法 | |
| CN115429883A (zh) | 用于联合治疗的抗肿瘤药物组合物 | |
| Von Hoff et al. | New drugs for patients with pancreatic cancer | |
| AU2015242786B2 (en) | Anti-tumor agent containing anti-tumor platinum complex, and anti-tumor effect enhancer | |
| CN118846070A (zh) | 一种用于治疗kras突变肿瘤的药物组合物及应用 | |
| JP2024515100A5 (https=) | ||
| JP7168575B2 (ja) | トリフルリジン／チピラシル塩酸塩、抗腫瘍白金錯体、及び免疫チェックポイント調節剤の新規組み合わせ物 | |
| RU2021135011A (ru) | Режимы дозирования при введении биспецифичного антитела против lag -3/pd-l1 | |
| US20250049802A1 (en) | Combination therapies and uses for treating cancer | |
| RU2778887C2 (ru) | Комбинация трифлуридина/типирацил гидрохлорида, противоопухолевого платинового комплекса и модулятора контрольных точек иммунного ответа | |
| US20220071982A1 (en) | Methods and uses for treating cancer | |
| Rosen et al. | 400 POSTER Early evidence of tolerability and clinical activity from a phase 1 study of TRC105 (anti-CD105 antibody) in patients with advanced refractory cancer | |
| Yamazaki et al. | 217TiP Dose-finding phase Ib study of FOLFOXIRI plus ramucirumabas first-line therapy for patients with metastatic colorectal cancer | |
| HK40015395A (en) | Combination between trifluridine/tipiracil hydrochloride, an anti-tumor platinum complex, and an immune checkpoint modulator | |
| Tolcher et al. | 403 POSTER Clinical responses in highly refractory solid tumor patients with oral MP-470, a multi-targeted tyrosine kinase inhibitor, in combination with standard of care chemotherapy regimens: preliminary report from a multi-institutional phase-1b clinical trial | |
| Calvo et al. | 586 Dose Determination of LY2603618 Administered in Combination with Pemetrexed and Cisplatin in Patients with Advanced Cancer | |
| Leong et al. | 402 POSTER A phase I study of gemcitabine, capecitabine and vandetanib in patients with advanced solid tumors with an expanded cohort in biliary and pancreatic malignancies | |
| Wakelee et al. | 401 POSTER A phase I study of enzastaurin (ENZ), an oral PKC inhibitor, in combination with erlotinib (ERL) administered orally daily to patients with advanced solid malignancies |